T-817MA is under clinical development by FUJIFILM Toyama Chemical and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect T-817MA’s likelihood of approval (LoA) and phase transition for Alzheimer’s Disease took place on 08 Jun 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their T-817MA Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

T-817MA overview

T-817MA is under development for the treatment of Alzheimer's disease, mild cognitive impairment due to Alzheimer’s disease and rehabilitation effects after stroke, unilateral upper limb paralysis (Hemiplegia) following cerebral infarction or cerebral hemorrhage. The drug candidate is administered by oral route. T-817MA is a neurotrophic agent and a maleate salt of T-817. T-817MA targets amyloid beta protein (amyloid precursor protein).

FUJIFILM Toyama Chemical overview

FUJIFILM Toyama Chemical, a subsidiary of Fujifilm Holdings Corp, develops and manufactures new diagnostic and therapeutic drugs for the treatment of oncology indications, central nervous system disorders and infectious diseases. The company offers products which include radiopharmaceuticals used for single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging; radioiodine for thyroid therapy; non-ionic X-ray contrast medium; and pharmaceuticals for diagnostic imaging. It also develops pipeline products for the treatment of respiratory and otorhinolaryngology infectious diseases, Alzheimer’s disease, prostate cancer, pheochromocytoma tumour and influenza virus. The company operates manufacturing factories in Toyama and Chiba regions. FUJIFILM Toyama Chemical is headquartered in Tokyo, Japan.

Quick View T-817MA LOA Data

Report Segments
  • Innovator
Drug Name
  • T-817MA
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.